MIC Injection is a prescription therapy used for metabolism and energy support.

Patients seeking support for metabolism and energy support may qualify after evaluation by a licensed provider.

Yes. MIC Injection is a compounded prescription preparation dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required to confirm clinical suitability, establish the appropriate dosing protocol, and integrate MIC therapy within your broader health and weight management plan.

MIC Injection is generally well tolerated. Common effects may include injection site reactions (mild redness, discomfort, or swelling), mild GI effects (nausea or GI upset), and a characteristic odor related to methionine metabolism. Fatigue or lightheadedness following injection has been reported occasionally. Report any unusual or persistent symptoms to your provider.

Patients with known hypersensitivity to methionine, inositol, choline, or any component of the formulation should not receive this preparation. Those with significant hepatic impairment should be evaluated carefully, as the lipotropic agents work through hepatic fat metabolism pathways. Patients with trimethylaminuria (inability to metabolize trimethylamine produced from choline) should not use choline-containing preparations without specialist guidance. Safety during pregnancy and breastfeeding has not been established for injectable use.

Choline may interact with cholinergic medications including certain Alzheimer's medications (acetylcholinesterase inhibitors) and parasympathomimetics, patients on these agents should disclose this to their provider. Methionine's role as a methyl donor may influence the metabolism of certain drugs. Patients on anticoagulants should monitor for any changes, as methionine's involvement in homocysteine metabolism may influence coagulation pathways over time. Provide a complete medication list to your provider before beginning treatment.

Patients with significant hepatic conditions, cardiovascular disease, metabolic disorders, or trimethylaminuria require individualized provider assessment before initiating MIC therapy. Those on lipid-modifying agents or weight loss medications, including GLP-1 agonists, should have their complete treatment plan reviewed to ensure MIC is appropriately integrated. Your provider will evaluate your complete medical history before prescribing.